GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 6:28 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 6:28 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Astrazeneca's Fasenra Gets Orphan Drug for Autoimmune Disease
by Zacks Equity Research
AstraZeneca (AZN) gets Orphan Drug status for Fasenra in the United States for the treatment of eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease.
3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far
by Zacks Equity Research
Glaxo's (GSK) shares have outperformed the industry this year. Here are some reasons for the same.
Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan
by Zacks Equity Research
GlaxoSmithKline (GSK) along with partner J&J gains approval for two-drug HIV regimen Juluca from the Japanese Ministry of Health, Labour and Welfare to benefit patients in the country.
Glaxo Inks Marketing Deal for Anaemia Candidate in Japan
by Zacks Equity Research
GlaxoSmithKline (GSK) signs a collaboration contract with Japan's Kyowa Hakko Kirin for future commercialization of daprodustat in Japan.
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca
Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth
by Zacks Equity Research
Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.
Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?
by Zacks Equity Research
Let???s see if GlaxoSmithKline plc (GSK) stock is a good choice for value-oriented investors right now from multiple angles.
Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs
by Zacks Equity Research
FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs
FDA Accepts Allergan's (AGN) sNDA for Anti-Infective Avycaz
by Zacks Equity Research
The FDA accepts Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.
Gilead's Vemlidy Gets Approval in China for HBV Infection
by Zacks Equity Research
Gilead (GILD) obtains approval for Vemlidy in China for the treatment of chronic hepatitis B in adults and adolescents.
Glaxo Seeks Label Expansion of Nucala in Pediatric Patients
by Zacks Equity Research
Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.
Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta
by Zacks Equity Research
Novartis (NVS) obtains FDA approval for the label expansion of Promacta. The CHMP also issues a positive opinion for the label expansion of Kisqali.
Merck's Keytruda Improves Survival in Esophageal Cancer Study
by Zacks Equity Research
Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer.
Has GlaxoSmithKline plc (GSK) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (GSK) Outperforming Other Medical Stocks This Year?
Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe
by Zacks Equity Research
Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.
Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.
Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ
by Zacks Equity Research
Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q3. The top line betters estimates.
Mylan (MYL) Earnings Beat, Revenues Miss Estimates in Q3
by Zacks Equity Research
Mylan's (MYL) Q3 revenues lag estimates due to persistent challenges in the North America segment.
Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Emergent (EBS) disappoints with weaker-than-expected results in the third quarter of 2018.
Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus
by Zacks Equity Research
Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.
Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View
by Zacks Equity Research
Glaxo (GSK) beats earnings and sales estimates in the third quarter. Strong sales growth of HIV and respiratory portfolio boosts sales while cost control initiatives aid bottom line.
Mylan (MYL) Q3 Earnings: Is a Disappointment in the Cards?
by Zacks Equity Research
Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when it reports Q3 results.
Glaxo (GSK) Beats Earnings Estimates in Q3, Revenue In-line
by Indrajit Bandyopadhyay
Glaxo beat earnings estimates while sales were in-line in the third quarter of 2018.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) is expected to see strong sales in its Vaccines business segment.
Gilead (GILD) Beats on Q3 Earnings & Sales, Updates View
by Zacks Equity Research
Gilead's (GILD) third-quarter results beat estimates. However, persistent decline in HCV sales is disappointing.